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Abstract
Background: Submission of study protocols to research ethics committees (RECs) constitutes one of the earliest
stages at which planned trials are documented in detail. Previous studies have investigated the amendments
requested from researchers by RECs, but the type of issues raised during REC review have not been compared by
sponsor type. The objective of this study was to identify recurring shortcomings in protocols of drug trials based on
REC comments and to assess whether these were more common among industry-sponsored or non-industry trials.
Methods: Retrospective analysis of 226 protocols of drug trials approved in 2010–2011 by three RECs affiliated to
academic medical centres in The Netherlands. For each protocol, information on sponsorship, number of
participating centres, participating countries, study phase, registration status of the study drug, and type and
number of subjects was retrieved. REC comments were extracted from decision letters sent to investigators after
review and were classified using a predefined checklist that was based on legislation and guidelines on clinical
drug research and previous literature.
Results: Most protocols received comments regarding participant information and consent forms (n = 182, 80.5%),
methodology and statistical analyses (n = 160, 70.8%), and supporting documentation, including trial agreements
and certificates of insurance (n = 154, 68.1%). Of the submitted protocols, 122 (54.0%) were non-industry and 104
(46.0%) were industry-sponsored trials. Non-industry trials more often received comments on subject selection
(n = 44, 36.1%) than industry-sponsored trials (n = 18, 17.3%; RR, 1.58; 95% CI, 1.01 to 2.47), and on methodology
and statistical analyses (n = 95, 77.9% versus n = 65, 62.5%, respectively; RR, 1.18; 95% CI, 1.01 to 1.37). Non-industry
trials less often received comments on supporting documentation (n = 72, 59.0%) than industry-sponsored trials
(n = 82, 78.8%; RR, 0.83; 95% CI, 0.72 to 0.95).
Conclusions: RECs identified important ethical and methodological shortcomings in protocols of both
industry-sponsored and non-industry drug trials. Investigators, especially of non-industry trials, should better prepare
their research protocols in order to facilitate the ethical review process.
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Background
Before new drugs can enter the market, they are exten-
sively investigated in clinical trials. Also after registration,
clinical drug research is important to improve our know-
ledge on safe and effective use of drugs [1]. In addition,
drugs are frequently used as tools to investigate physi-
ology and pathophysiology in humans in vivo. Prior to the
recruitment of trial participants, research protocols need
to be evaluated by research ethics committees (RECs) to
assess whether all scientific, ethical, and legal require-
ments for conducting drug research with human subjects
are met [2,3]. Studies may raise questions of informed
consent, adequate subject selection, scientific validity, ac-
ceptable risk-benefit ratios, and the value of the research
to society in relation to the burdens to participants [4].
Submission of study protocols to RECs constitutes
one of the earliest stages at which planned trials are
documented in detail. Prior studies on ethical review of
protocols involving human subjects have investigated
the type of amendments and clarifications requested from
researchers by RECs. For many protocols, some type of
amendment was needed before approval [5-7]. RECs fre-
quently commented on inadequacies in informed consent
forms, possible risks to participants, methodological and
statistical issues in protocols, and missing or incorrect
supporting documentation [5-10]. However, several stud-
ies on REC review included small numbers of protocols
[5,9,10], or focused on protocols submitted to single RECs
so resulting findings may be specific to the committee
studied [5,6]. In addition, although the issues raised by
RECs may depend on the intervention tested, previous
studies have included protocols regardless of the type of
intervention [5-8,10].
The type and extent of shortcomings detected by RECs
may also be related to sponsorship of trials. Pharmaceutical
companies generally have larger budgets and a better re-
search infrastructure compared to non-profit organizations,
which could lead to higher protocol quality. However, it has
also been suggested that the pharmaceutical industry’s pur-
suit of profit and favourable study results may have negative
effects on research quality [11,12]. Studies based on pub-
lished trials have indicated that methodological quality is
comparable for industry-sponsored and non-industry trials
[12-14]. However, for a cohort of trials submitted to a
Dutch REC, it was shown that non-industry trials have
more problems in recruiting the required number of sub-
jects than studies initiated by pharmaceutical companies
[15]. This was confirmed in a study with protocols ap-
proved by RECs in Switzerland, Germany, and Canada
indicating that industry-sponsorship was associated with
lower rates of trial discontinuation due to poor recruit-
ment [16]. The shortcomings of protocols that are identi-
fied during REC review have not been compared by
sponsor type though.
The objective of this explorative study was to identify
recurring shortcomings in protocols of drug trials and to
assess whether these are more common among industry-
sponsored or non-industry trials. Protocols submitted to
three RECs affiliated to academic medical centres in The
Netherlands were included and REC decision letters sent
to researchers after review were accessed. REC comments
were extracted and classified using a predefined checklist
that was based on legislation and guidelines on clinical
drug research and previous literature. It was examined
whether there was a relationship between the occurrence
of certain types of comments and industry sponsorship.
Methods
Selection of RECs and protocols
All eight RECs affiliated to academic medical centres in
The Netherlands were asked to provide access to submit-
ted protocols and their correspondence with investiga-
tors. These eight committees together review 70% of all
medical research with human subjects conducted in The
Netherlands [17]. RECs located in Nijmegen (CMO),
Amsterdam (METc VUmc) and Leiden (CME) agreed to
participate. Other committees did not participate due to
logistical or confidentiality issues. All protocols approved
in 2010–2011 were included, if they were classified as tri-
als with medicinal products.
Extraction of trial characteristics
For each protocol, information was retrieved on sponsor
type, number of participating centres, participating coun-
tries, study phase, type of subjects, anticipated number of
subjects, and whether the study drug was registered in
The Netherlands. Data were extracted from a standard-
ized form used in The Netherlands to prospectively docu-
ment characteristics of planned trials (ABR form). Trials
were classified as non-industry or industry-sponsored
trials. For industry-sponsored trials, a pharmaceutical com-
pany was explicitly reported as the study sponsor in the
ABR form. We verified whether the company indeed had
the overall responsibility for the conduct of the trial using
the trial protocol, clinical trial agreement and corres-
pondence between the REC and investigators. Non-
industry trials were investigator-initiated studies for
which no associations with pharmaceutical companies
were reported, or investigator-initiated studies that re-
ceived study medication or financial support from
manufacturers which did not have any responsibility
for the content of the protocol.
Extraction and classification of REC comments
For the classification of REC comments, a comprehensive
checklist was composed prior to accessing REC decision
letters (Table 1). The content of this checklist was based
on national and international legislation and guidelines
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on the conduct of drug research with human subjects,
and previous literature on this topic [2-4,18-21]. This re-
sulted in a checklist consisting of thirteen review criteria,
that need to be considered by RECs to assess whether all
scientific, ethical, and legal requirements for drug trials
are met. For each trial, the issues raised by RECs were ex-
tracted from REC decision letters that were sent to inves-
tigators after protocol review. As these comments were
not described in a standardized manner in REC letters,
all data were first fully transcribed and subsequently cate-
gorized using the classification checklist. During the
extraction of REC comments, there was no blinding for
sponsorship as this was unfeasible due to logistical rea-
sons. In this explorative study, the categorization of com-
ments was performed by one author. Submitted protocols
could be discussed by RECs at several occasions before re-
ceiving approval. All correspondence between RECs and
investigators prior to approval was included in this study.
Table 1 Classification checklist for REC review of protocols of drug trials
Review criteria Definition
1. Proportionality Risks and burdens to subjects are reasonable in relation to anticipated benefits
Trial leads to important medical knowledge and/or considerable health benefits
Participation does not involve unacceptable/disproportionate risks or burdens to subjects, use of placebo in trial is
ethically justified
2. Minimisation of risks &
burdens
Risks and burdens to subjects are minimized
Research question cannot be answered without inclusion of human subjects
Research question cannot be answered by more simple or less riskful/burdensome research
3. Privacy & confidentiality Adequate provisions are made to protect privacy of subjects and maintain confidentiality of data and body tissues
Trial data and body tissues are adequately coded, stored and protected, with restricted access for third parties
4. Patient safety Adequate provisions are made to ensure safety of subjects during the trial
Collected data are adequately monitored and (if necessary) a Data and Safety Monitoring Board (DSMB) is installed
Individual and group level stopping criteria are adequate
5. Recruitment process Recruitment methods and payments to subjects are acceptable
Investigator has access to population that allows recruitment of required number of subjects
Subjects are given adequate opportunity and time to ask questions and decide about participation
6. Information sheet &
consent form
Subject information sheet & consent form contain all required elements
The length, structure and language use of the information sheet & consent form will allow subjects to understand
them correctly
7. Subject selection Subject selection is appropriate to answer the research question
Inclusion and exclusion criteria are adequate and complete, equity in subject selection
8. Protection vulnerable
subjects
When vulnerable subjects are included, there are additional safeguards to protect their rights and well-being
No vulnerable subjects are included, unless they may benefit themselves from participation or trial cannot be
conducted without them
9. Methodology & statistical
analysis
Trial design/methodology is appropriate and properly motivated in protocol
Selected primary & secondary endpoints and dosage regimen are appropriate
Sample size calculations and planned statistical analyses are adequate
10. Product information Product information on the medicinal product(s) used in the study is adequate
Investigator’s Brochure (IB) and Investigational Medicinal Product Dossier (IMPD)/ Summary of Product
Characteristics (SPC) are acceptable
11. Supporting
documentation
Other documents submitted as part of the research proposal are acceptable
Data in ABR form are complete and correct and the Clinical Trial Agreement is in accord with Dutch regulations
Required insurances for medical research with human subjects are arranged
12. Facilities & research staff Research staff members are experienced and qualified to conduct trial procedures
Investigator has adequate facilities to conduct the trial
13. Financial aspects All costs incurring during the trial are adequately covered
Compensation fees paid to investigators or institutions are proportional to the size, nature, and purpose of the trial
Conditions (e.g. financial interests) leading to conflicts of interest are prevented
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Furthermore, the number of days between protocol sub-
mission and final REC approval was determined, which
consisted of time attributable to RECs and time used by
researchers to respond to comments.
Statistical analysis
The association between sponsor type and the number
of trials that received comments after REC review was
analyzed using generalized linear models (log-binomial)
for each of the thirteen review criteria. We controlled
for the REC that reviewed the protocol by including
both sponsor type and REC as predictors in the model,
and tested for interaction between sponsor type and
REC. Associations between sponsor type and the num-
ber of trials that received comments were estimated with
relative risks (RRs) and 95% confidence intervals (CIs).
The total time between protocol submission and REC
approval was compared by sponsor type and REC using
a two-way ANOVA. We tested for interaction between
sponsor type and REC. As time to approval was posi-
tively skewed, data were Ln-transformed before testing
for differences between groups. P < .05 was considered
statistically significant. Because of the explorative char-
acter of this study, P-values were not adjusted for mul-
tiple comparisons. Statistical analyses were performed
using SPSS software (version 20; Chicago, Illinois).
Ethics
To assure confidentiality of information in submitted
protocols and correspondence between RECs and inves-
tigators, confidentiality agreements were signed before
gaining access to the data. As standard REC procedures
were unchanged, investigators were not informed about
this study. Formal REC approval was not required for
this study as no human subjects were involved.
Results
In 2010 and 2011, 226 protocols of drug trials were
approved by three Dutch RECs (Nijmegen, n = 74;
Amsterdam, n = 76; Leiden, n = 76) (Table 2). In 2010,
123 (54.4%) protocols were approved, compared to 103
(45.6%) in 2011. Of the submitted trials, 104 (46.0%)
were sponsored by the pharmaceutical industry and 122
(54.0%) were non-industry trials, of which 31 were finan-
cially or materially supported by a for-profit organisation
(13.7% of the total number of trials).
Most studies were multicentre trials (n = 126; 55.8%)
and were mostly conducted in The Netherlands only
(n = 131; 58.0%) (Table 2). 31 of the 126 multicentre
studies (24.6%) were performed in The Netherlands only,
whereas 95 (75.4%) were multinational multicentre stud-
ies. Trials were categorized as phase 1 (n = 21; 9.3%),
phase 2 (n = 62; 27.4%), phase 3 (n = 62; 27.4%), phase
4 (n = 17; 7.5%), or other trials involving medicinal
products (n = 64; 28.3%). In 50 trials (22.1%), a drug regis-
tered in The Netherlands for the same indication/dosage
as studied in the trial protocol was used, while 74 (32.7%)
Table 2 Characteristics of drug trials approved in
2010-2011
Protocols
Total, n (%) 226 (100)
REC
Nijmegen 74 (32.7)
Amsterdam 76 (33.6)
Leiden 76 (33.6)
Year of approval
2010 123 (54.4)
2011 103 (45.6)
Sponsor type
Non-industry 91 (40.3)
Non-industry, supported by industry 31 (13.7)
Industry-sponsored 104 (46.0)
Number of centres
Single centre 100 (44.2)
Multicentre 126 (55.8)
NL only or international trial
NL trial 131 (58.0)
International trial 95 (42.0)
Phase
Phase 1 21 (9.3)
Phase 2 62 (27.4)
Phase 3 62 (27.4)
Phase 4 17 (7.5)
Other 64 (28.3)
Study drug registered in NL
Yes, for the same indication/dosage as studied in
protocol
50 (22.1)
Yes, for different indication/dosage than studied in
protocol
74 (32.7)
No 79 (35.0)
Not reported whether drug was registered in NL 23 (10.2)
Type of subjects
Adult subjects capable of giving informed consent 208 (92.0)
Adult subjects not capable of giving informed consent
and/or minors <18 years
7 (3.1)
Adult subjects capable of giving informed consent and
adults not capable of giving informed consent or minors
<18 years
11 (4.9)
Anticipated number of subjects, median (IQR)
Number of subjects (total) 59 (24–240)
Number of subjects (NL trials) 34 (20–60)
Number of subjects (international trials) 300 (120–800)
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used drugs that were registered for a different indication/
dosage than studied in the protocol, and 79 (35.0%)
used drugs that were not registered in the Netherlands.
For 23 trials (10.2%), it was not reported whether the
study drug was registered. Most trials recruited adult
subjects capable of giving informed consent (n = 208;
92.0%), while 7 (3.1%) trials included adult subjects
not capable of giving informed consent and/or minors
<18 years, and 11 (4.9%) included both types of subjects.
The median number of subjects per trial was 59 (inter-
quartile range (IQR), 24–240). The median number
of subjects in trials conducted in The Netherlands only
was 34 (IQR, 20–60), compared to 300 (IQR, 120–800)
in multinational trials.
In Table 3, random examples of comments raised dur-
ing REC review are presented to illustrate each type of
shortcoming. Table 4 shows the number of trials that re-
ceived comments for each of the review criteria. Most tri-
als received comments on the subject information sheet
and consent form (n = 182, 80.5%), methodology and
planned statistical analyses (n = 160, 70.8%), and support-
ing documentation, including clinical trial agreements
and certificates of insurance (n = 154, 68.1%). In contrast,
RECs rarely commented on the minimization of risks
and burdens to subjects (n = 26, 11.5%), financial aspects
(n = 39, 17.3%), and the protection of vulnerable subjects
(n = 9, 4.0%).
Non-industry trials more often received comments on
subject selection (n = 44, 36.1%) than industry-sponsored
trials (n = 18, 17.3%; RR, 1.58; 95% CI, 1.01 to 2.47)
(Table 4). More non-industry trials received comments
on methodology and statistical analyses (n = 95, 77.9%)
compared to industry-sponsored trials (n = 65, 62.5%; RR,
1.18; 95% CI, 1.01 to 1.37). In contrast, non-industry tri-
als less often received comments on supporting docu-
mentation (n = 72, 59.0%) than industry-sponsored trials
(n = 82, 78.8%; RR, 0.83; 95% CI, 0.72 to 0.95). There was
a non-significant trend indicating that non-industry trials
more often received comments related to facilities and
research staff (n = 39, 32.0%) compared to industry-
sponsored trials (n = 18, 17.3%; RR, 1.60; 95% CI, 0.98 to
2.60). The proportion of trials that received comments
was comparable between RECs for protection of vulner-
able subjects and product information. For the other re-
view criteria, the proportion of trials with comments was
significantly different between RECs (data not shown).
For product information and supporting documentation,
the interaction between sponsor type and REC was
p < .05. However, RRs for the association between spon-
sorship and these review criteria were comparable for the
individual RECs and the interaction was considered not
relevant with regard to the effect of sponsorship.
The median time to protocol approval was 112 days
(IQR, 78–163) (Table 5). Time to approval was not
significantly different between industry-sponsored (119
days; IQR, 84–169) and non-industry trials (101 days; IQR,
75–158, p = .298). Time to approval was longer for proto-
cols submitted in Nijmegen (148 days; IQR, 89–203) than
for those submitted in Amsterdam (113 days; IQR 87–150)
or Leiden (91 days; IQR, 65–127, overall p = .000). There
was no interaction between sponsor type and REC regard-
ing time to approval.
Discussion
In this study, recurring shortcomings in protocols of drug
trials were identified based on REC comments and it was
assessed whether these were more common among
industry-sponsored or non-industry trials. Most protocols
received comments regarding informed consent forms,
methodology and planned statistical analyses, and sup-
porting documentation including clinical trial agreements
and certificates of insurance. This corresponds to findings
of previous studies on the issues raised by RECs [5-7,9]. In
addition, a recent evaluation of the Dutch law on medical
research with human subjects also indicated that RECs
give a lot of attention to improvement of participant infor-
mation [22]. RECs rarely addressed the minimization of
risks and burdens to subjects, financial aspects, and the
protection of vulnerable subjects. The last finding is
hardly surprising, as 90% of the protocols included adult
subjects capable of giving informed consent.
Non-industry protocols more often received comments
related to methodology and statistical analyses and the se-
lection of participants than industry-sponsored protocols,
while research based on published trials indicated that
methodological quality was comparable for industry-
sponsored and non-industry trials [12-14]. RECs may play
an important role in improving the quality of submitted
protocols, which could explain the observed absence of
substantial differences in methodological quality in rela-
tion to sponsorship among published trials. In contrast,
industry-sponsored trials more often received comments
on supporting documentation submitted alongside proto-
cols. This difference seemed to be associated with REC
comments on clauses in clinical trial agreements for
industry-sponsored trials, in particular regarding the pub-
lication of results and premature termination of trials.
The time to protocol approval was comparable for
non-industry and industry-sponsored trials, but was sig-
nificantly different between RECs. Time to approval may
be related to the quality and characteristics of submitted
protocols, but may also reflect the efficiency of the re-
view process. The REC in Nijmegen received lower pro-
portions of industry-sponsored studies and trials with
drugs not registered in The Netherlands. There may be
other differences between submitted protocols that were
not detected in this study. In Leiden and Amsterdam,
protocols are reviewed by science committees before
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Table 3 Examples of REC comments on protocols of drug trials
Review criteria Example
1. Proportionality “The committee has serious doubts regarding the proportionality of the study, because the trial is
very burdensome for participants and a number of potentially risky interventions are being combined”.
“The committee would like to hear the expected benefit(s) of the study drug from the investigators; the
clinical relevance of the trial is not clear”.
2. Minimisation of risks & burdens “The committee wonders why it is necessary to burden patients with completion of the proposed
quality of life questionnaires; much is already known about the quality of life of this group of patients”.
“The investigators need to convince the committee of the usefulness of repeating skin biopsies
and synovial biopsies”.
3. Privacy & confidentiality “The committee notes that questionnaires should be stored coded; there should be no personal
data on the questionnaires, as is the case now for a number of questionnaires”.
“Trial medication is home delivered to participants by courier; the committee wants to know
which provisions are made to prevent that participant addresses are known by the manufacturer”.
4. Patient safety “The committee wonders why no individual and group level stopping rules are defined and no DSMB
is installed for this trial”.
“The committee wonders whether it is possible, in view of patient safety, to sequentially include
participants in this trial”.
5. Recruitment process “The minimal time of 24 h to decide about participation is too short considering the chance of
placebo treatment, and the potential risks and burdens of participating; it should be minimally 5 days”.
“The committee is concerned whether enough patients can be included; this type of cancer is
particularly seen in patients with metastases, but these patients cannot participate in the trial”.
6. Information sheet & consent form “The written subject information is too long and too difficult (regarding both vocabulary and style);
the committee would like to see a completely rewritten version, understandable to a layperson”.
“It should be more clearly explained to which extent the trial treatment deviates from the standard
treatment and what subjects must undergo additionally by participating in the trial”.
7. Subject selection “The committee asks the investigators why they do not select subjects at inclusion based on pain
complaints, while this is an objective of the trial”.
“The committee has the impression that the exclusion criteria are not complete, considering the SPC
text; in particular, the committee believes that children with heart disease or kidney failure should be excluded”.
8. Protection vulnerable subjects “The committee would like to hear substantive arguments for the need to include minors; the
investigators have not justified why this group should be involved in this trial”.
“The committee would like to hear how subjects and their relatives are informed on the procedures
in case of resistance by subjects during the trial”.
9. Methodology & statistical analysis “The sample size calculation does not reflect the primary analysis described as a (mixed effect)
repeated measures ANOVA; the current calculation does not reflect that there are 10 VAS pain measurements”.
“The trial is designed as cross-over; because of potential carry-over effects, the committee believes
that a parallel comparison of 2 groups should be preferred”.
10. Product information “The committee needs more information on the endothelin receptor antagonists; information on
product characteristics, pharmacological characteristics, efficacy and safety, and pharmacokinetics is missing”.
“The data in the IMPD are from 1997; the committee wants to know whether this batch is still
being used or whether there has been a more recent production”.
11. Supporting documentation “The text in the Clinical Trial Agreement on (premature) termination of the trial and publication of
results does not correspond to provisions in the Dutch regulation on assessment of Clinical Trial Agreements”.
“The committee wants to know whether the sponsor takes responsibility for the clinical trial
liability insurance for all participating centres”.
12. Facilities & research staff “A student cannot be principal investigator for this trial, because a student lacks experience and
cannot take final responsibility for the trial”.
“The committee believes that, considering the treatment during the trial, an oncologist should be
involved in the design and conduct of the trial”.
13. Financial aspects “The committee would like to see an exact justification of the 100.000 euro that the department
will receive for conducting the trial”.
“The committee does not agree with the independent physician appointed for 3 of the participating
centres; this person also works as a physician for the pharmaceutical company sponsoring this trial”.
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submission to the REC, which may reduce the time
needed by RECs to review methodological aspects. In
addition, investigators submitting protocols to the REC
in Leiden are invited to discuss their study with a pre-
advisor prior to REC meetings. In The Netherlands,
RECs should complete reviews of drug trials within sixty
days [18]. The clock stops when RECs ask questions to
investigators, and restarts when the required information
is provided. However, as time to approval consisted of
time attributable to RECs and time used by researchers
to respond to comments, no definite conclusions can be
drawn.
Due to the retrospective design of this study, included
protocols were already reviewed before RECs were asked
to participate in this study and the behaviour of REC
members was not influenced by awareness of an ongoing
investigation. As we had unrestricted access to submitted
protocols and correspondence between RECs and re-
searchers, we were able to extract trial characteristics and
REC comments without having to obtain permission from
researchers or rely on a survey of researchers to obtain
these data, excluding the introduction of response bias
[23]. Although there was no response bias with respect to
individual studies, there may be a response bias in terms
of RECs if the committees that declined to take part some-
how differed from participating committees. Nevertheless,
by inclusion of protocols submitted to three RECs that are
among the eight largest committees in The Netherlands
regarding the number of studies annually reviewed, more
than 20% of all drugs trials approved in The Netherlands
in 2010–2011 were evaluated.
Many studies have focused on the methodological
quality of published trials [12-14] or followed protocols
approved by RECs until publication [23,24]. In contrast,
we identified shortcomings of protocols based on REC
comments raised prior to trial initiation. Quality assess-
ments in previous studies may have been affected by in-
complete reporting in published articles, as evaluations
of the risk of bias in trials may have been confused with
assessment of the adequacy of reporting [25]. REC com-
ments may not inherently provide an objective reflection
of the quality of submitted protocols, as it has been
shown that REC review is variable regarding the deci-
sions made on protocols [26-28]. Comments that are
raised may be influenced by local variation in require-
ments, and may vary by REC even for the same protocol
Table 4 Analysis of REC comments - non-industry
(n = 122) vs industry-sponsored trials (n = 104)
Review criteria Protocols with
comments, n (%)
Relative risk
(95% CI)*
P-value
1. Proportionality 61 (27.0)
Non-industry 34 (27.9) 0.95 (0.62-1.45) .805
Industry 27 (26.0)
2. Minimisation of risks
& burdens
26 (11.5)
Non-industry 15 (12.3) 0.92 (0.44-1.91) .820
Industry 11 (10.6)
3. Privacy &
confidentiality
63 (27.9)
Non-industry 29 (23.8) 0.93 (0.65-1.34) .695
Industry 34 (32.7)
4. Patient safety 61 (27.0)
Non-industry 36 (29.5) 1.31 (0.84-2.04) .228
Industry 25 (24.0)
5. Recruitment
process
47 (20.8)
Non-industry 30 (24.6) 1.05 (0.63-1.73) .866
Industry 17 (16.3)
6. Information sheet
& consent form
182 (80.5)
Non-industry 100 (82.0) 1.04 (0.94-1.13) .468
Industry 82 (78.8)
7. Subject selection 62 (27.4)
Non-industry 44 (36.1) 1.58 (1.01-2.47) .045
Industry 18 (17.3)
8. Protection
vulnerable subjects
9 (4.0)
Non-industry 6 (4.9) 1.53 (0.38-6.07) .549
Industry 3 (2.9)
9. Methodology &
statistical analysis
160 (70.8)
Non-industry 95 (77.9) 1.18 (1.01-1.37) .038
Industry 65 (62.5)
10. Product information 65 (28.8)
Non-industry 38 (31.1) 1.16 (0.75-1.78) .507
Industry 27 (26.0)
11. Supporting
documentation
154 (68.1)
Non-industry 72 (59.0) 0.83 (0.72-0.95) .006
Industry 82 (78.8)
12. Facilities &
research staff
57 (25.2)
Non-industry 39 (32.0) 1.60 (0.98-2.60) .060
Industry 18 (17.3)
Table 4 Analysis of REC comments - non-industry
(n = 122) vs industry-sponsored trials (n = 104) (Continued)
13. Financial aspects 39 (17.3)
Non-industry 25 (20.5) 1.65 (0.90-3.01) .103
Industry 14 (13.5)
* Relative risks are controlled for the REC that reviewed the protocol.
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with multicenter trials [28,29]. In this study, the propor-
tion of protocols that received comments varied by REC
for most of the review criteria. It is difficult to determine
whether this reflects variable protocol quality or variable
review by RECs.
This study has certain limitations. First, we focused on
protocols submitted to Dutch RECs. In addition to the
variability found between RECs within the same country,
ethical review processes also vary between countries
[30,31]. This limits the generalizability of our findings to
non-Dutch RECs, although 40% of the included trials
were conducted in multiple countries. This study in-
cluded trials that eventually received a favourable opin-
ion. We did not evaluate protocols that were rejected by
RECs. Although only 3% of all trials annually reviewed
in The Netherlands are rejected [17], it may be interest-
ing to consider this group as the chance of rejection
might be associated with sponsorship. However, this was
beyond the scope of the current study.
In this explorative study, the categorization of REC
comments was performed by one author, while this
would ideally have been done by two or more independ-
ent assessors and disagreements resolved by consensus.
The categorisation of REC comments may be considered
as subjective. However, to our knowledge, this is the first
study in which shortcomings of protocols of drug trials
as identified by RECs have been compared by sponsor
type. The internal and external validity of the classifica-
tion checklist used in this study could be further verified
in future studies with different assessors and different
samples of research protocols submitted to RECs.
Finally, industry-sponsored and non-industry trials
may not be similarly addressed by RECs. Pharmaceutical
companies commonly perform large multinational trials,
while non-industry trials are more often initiated and
conducted by local investigators. In this study, 90% of
the industry-sponsored trials were multicenter studies,
compared to 30% of the non-industry trials. RECs that
are involved at a single site of a large multicenter trial
might feel constrained in their ability to modify the trial
design and limited in what changes they can make to
informed consent forms. In addition, multinational in-
dustry trials may have already implemented comments
from RECs in other countries before submission to
Dutch RECs.
Conclusions
In conclusion, RECs identified important ethical and meth-
odological shortcomings in protocols of both industry-
sponsored and non-industry drug trials. Investigators,
especially of non-industry trials, should better prepare their
research protocols in order to facilitate the ethical review
process.
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Table 5 Time to approval of submitted protocols
Time to approval in
days, median (IQR)
P-value
Total protocols (n = 226) 112 (78–163)
Sponsor type .298
Non-industry (n = 122) 101 (75–158)
Industry-sponsored (n = 104) 119 (84–169)
REC .000
Nijmegen (n = 74) 148 (89–203)
Amsterdam (n = 76) 113 (87–150)
Leiden (n = 76) 91 (65–127)
Nijmegen vs Amsterdam .026
Nijmegen vs Leiden .000
Amsterdam vs Leiden .001
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